NanoSyrinx Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.98M

  • Investors
  • 16

NanoSyrinx General Information

Description

Developer of a novel biologics drug research platform designed to serve the biopharmaceutical sector. The company leverages a synthetic biology approach to create a completely novel method for targeted drug delivery of therapeutic proteins and peptides to cell interiors and delivers payloads directly to the cytosol of targeted cells, enabling medical practitioners to improve efficacy and treatment outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 27D, The Venture Centre, Sir William Lyons Road
  • University of Warwick Science Park, West Midlands
  • Coventry CV4 7EZ
  • England, United Kingdom
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Unit 27D, The Venture Centre, Sir William Lyons Road
  • University of Warwick Science Park, West Midlands
  • Coventry CV4 7EZ
  • England, United Kingdom

NanoSyrinx Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NanoSyrinx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 28-Nov-2025 $4.98M Completed Product Development
5. Later Stage VC (Series A) 13-Aug-2024 Completed Product Development
4. Seed Round 10-Nov-2022 Completed Generating Revenue
3. Grant 01-Jul-2020 Completed Startup
2. Accelerator/Incubator 01-Jan-2019 Completed Startup
1. University Spin-Out 01-Jan-2018 Completed Startup
To view NanoSyrinx’s complete valuation and funding history, request access »

NanoSyrinx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Seed Ordinary
Seed Ordinary 2,875,900 $0.000001 $2.16 $2.16 1x $2.16 43.63%
Seed Ordinary 328,100 $0.000001 $1.3 $1.3 1x $1.3 4.98%
To view NanoSyrinx’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NanoSyrinx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel biologics drug research platform designed to serve the biopharmaceutical sector. The company levera
Drug Delivery
Coventry, United Kingdom
21 As of 2025

Baton Rouge, LA

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NanoSyrinx Competitors (2)

One of NanoSyrinx’s 2 competitors is Therapeutic Peptides, a Corporate Backed or Acquired company based in Baton Rouge, LA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Therapeutic Peptides Corporate Backed or Acquired Baton Rouge, LA
Immupharma Corporation London, United Kingdom
You’re viewing 2 of 2 competitors. Get the full list »

NanoSyrinx Patents

NanoSyrinx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202509404-D0 A modified tail fibre Pending 13-Jun-2025
GB-202417349-D0 Method of purification Pending 26-Nov-2024
WO-2026115259-A1 Method of purification Pending 26-Nov-2024
AU-2020288380-A1 Leader sequence Active 07-Jun-2019
AU-2020288380-B2 Leader sequence Active 07-Jun-2019 C07K14/195
To view NanoSyrinx’s complete patent history, request access »

NanoSyrinx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NanoSyrinx Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Proven Connect Impact Investing Minority
Saras Capital (England) Venture Capital Minority
BGF (Financial Services) Growth/Expansion Minority
Lilly USA Corporation Minority
Alderley Park Accelerator/Incubator Minority
You’re viewing 5 of 16 investors. Get the full list »

NanoSyrinx FAQs

  • When was NanoSyrinx founded?

    NanoSyrinx was founded in 2018.

  • Where is NanoSyrinx headquartered?

    NanoSyrinx is headquartered in Coventry, United Kingdom.

  • What is the size of NanoSyrinx?

    NanoSyrinx has 21 total employees.

  • What industry is NanoSyrinx in?

    NanoSyrinx’s primary industry is Drug Delivery.

  • Is NanoSyrinx a private or public company?

    NanoSyrinx is a Private company.

  • What is the current valuation of NanoSyrinx?

    The current valuation of NanoSyrinx is .

  • What is NanoSyrinx’s current revenue?

    The current revenue for NanoSyrinx is .

  • How much funding has NanoSyrinx raised over time?

    NanoSyrinx has raised $25M.

  • Who are NanoSyrinx’s investors?

    Proven Connect, Saras Capital (England), BGF (Financial Services), Lilly USA, and Alderley Park are 5 of 16 investors who have invested in NanoSyrinx.

  • Who are NanoSyrinx’s competitors?

    Therapeutic Peptides and Immupharma are competitors of NanoSyrinx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process